A C Prats
Overview
Explore the profile of A C Prats including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zamora A, Nougue M, Verdu L, Balzan E, Draia-Nicolau T, Benuzzi E, et al.
Nat Commun
. 2024 Jan;
15(1):221.
PMID: 38177096
Lymphedema (LD) is characterized by the accumulation of interstitial fluid, lipids and inflammatory cell infiltrate in the limb. Here, we find that LD tissues from women who developed LD after...
2.
Prats A, Van den Berghe L, Rayssac A, Ainaoui N, Morfoisse F, Pujol F, et al.
Microvasc Res
. 2013 Jun;
89:25-33.
PMID: 23747987
Anti-angiogenic and anti-lymphangiogenic drugs slow tumor progression and dissemination. However, an important difficulty is that a tumor reacts and compensates to obtain the blood supply needed for tumor growth and...
3.
Garmy-Susini B, Delmas E, Gourdy P, Zhou M, Bossard C, Bugler B, et al.
Circ Res
. 2004 Apr;
94(10):1301-9.
PMID: 15073041
Both 17beta-estradiol (E2) and fibroblast growth factor-2 (FGF2) stimulate angiogenesis and endothelial cell migration and proliferation. The first goal of this study was to explore the potential link between this...
4.
Schneider R, Agol V, Andino R, Bayard F, Cavener D, Chappell S, et al.
Mol Cell Biol
. 2001 Nov;
21(23):8238-46.
PMID: 11710333
No abstract available.
5.
Galy B, Creancier L, Prado-Lourenco L, Prats A, Prats H
Oncogene
. 2001 Aug;
20(34):4613-20.
PMID: 11498784
Tumour suppressor p53 has been shown to inhibit fibroblast growth factor 2 expression post-transcriptionally in cultured cells. Here we have investigated the mechanism responsible for this post-transcriptional blockade. Deletion mutagenesis...
6.
Nanbru C, Prats A, Droogmans L, Defrance P, Huez G, Kruys V
Oncogene
. 2001 Jul;
20(31):4270-80.
PMID: 11464293
The human c-myc proto-oncogene is transcribed from four alternative promoters (P0, P1, P2, and P3) giving rise to mRNAs having 5' leader sequences of various length. The c-myc P0 mRNA...
7.
Galy B, Creancier L, Zanibellato C, Prats A, Prats H
Oncogene
. 2001 Apr;
20(14):1669-77.
PMID: 11313915
Fibroblast growth factor-2 (FGF-2) is a powerful mitogen and angiogenic factor whose expression is strongly regulated at the translational level. The constitutive upregulation of FGF-2 isoforms in transformed cells prompted...
8.
Creancier L, Mercier P, Prats A, Morello D
Mol Cell Biol
. 2001 Mar;
21(5):1833-40.
PMID: 11238920
The expression of c-myc proto-oncogene, a key regulator of cell proliferation and apoptosis, is controlled at different transcriptional and posttranscriptional levels. In particular, the c-myc mRNA contains an internal ribosome...
9.
Waysbort A, Bonnal S, Audigier S, Esteve J, Prats A
FEBS Lett
. 2001 Feb;
490(1-2):54-8.
PMID: 11172810
Retrovirus genomic mRNA exhibits a several hundred nucleotides-long untranslated region (5' UTR) which encloses many control elements required for retrovirus replication. In addition, this 5' UTR contains translation regulatory elements,...
10.
Creancier L, Morello D, Mercier P, Prats A
J Cell Biol
. 2000 Jul;
150(1):275-81.
PMID: 10893274
Fibroblast growth factor 2 (FGF-2) is a powerful mitogen involved in proliferation, differentiation, and survival of various cells including neurons. FGF-2 expression is translationally regulated; in particular, the FGF-2 mRNA...